Daniel Jenkin

Employment

• Pandemic Science Institute, University of Oxford
  2022 - Present
• Jenner Institute
  2018 - Present
• University of Oxford

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (24)

• Lassa fever countermeasures gather pace
  Nature Medicine 2026 DOI: 10.1038/s41591-026-04478-4
  +Save
• Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial
  The Lancet Microbe 2025 DOI: 10.1016/j.lanmic.2024.101022
  +Save
• Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
  Vaccine 2025 DOI: 10.1016/j.vaccine.2024.126582
  +Save
• Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
  The Lancet Infectious Diseases 2024 DOI: 10.1016/s1473-3099(24)00143-9
  +Save
• Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
  The Lancet Infectious Diseases 2023 DOI: 10.1016/s1473-3099(23)00068-3
  +Save
• Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
  Clinical and Experimental Immunology 2023 DOI: 10.1093/cei/uxad013
  +Save
• Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
  eBioMedicine 2022 DOI: 10.1016/j.ebiom.2022.104298
  +Save
• Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
  The Lancet Microbe 2022 DOI: 10.1016/s2666-5247(22)00126-4
  +Save
• Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
  Vaccine 2022 DOI: 10.1016/j.vaccine.2022.06.008
  +Save
• An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
  Natalie G. Marchevsky, Grace Li, Parvinder K. Aley +21 more
  EBioMedicine 2022 DOI: 10.1016/j.ebiom.2022.104128
  +Save
• Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.
  Frontiers in immunology 2022 DOI: 10.3389/fimmu.2022.795463
  +Save
• SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
  Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou +97 more
  Cell 2022 DOI: 10.1016/j.cell.2021.12.046
  +Save
• Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
  Amy L. Flaxman, Natalie G. Marchevsky, Daniel Jenkin +97 more
  Lancet (London, England) 2021 DOI: 10.1016/s0140-6736(21)01699-8
  +Save
• A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
  Nature communications 2021 DOI: 10.1038/s41467-021-24906-y
  +Save
• Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
  John Frater, Katie Ewer, Ane Ogbe +66 more
  The lancet. HIV 2021 DOI: 10.1016/s2352-3018(21)00103-x
  +Save
• Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
  Vaccines 2021 DOI: 10.3390/vaccines9030262
  +Save
• Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
  Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley

  +62 more

  • Cristina V. Ariani
  • Brian Angus
  • Sagida Bibi
  • Beth Blane
  • David Bonsall
  • +57 more
  The Lancet 2021 DOI: 10.1016/s0140-6736(21)00628-0
  +Save
• Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
  Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Christina Dold +97 more
  Nature Medicine 2021 DOI: 10.1038/s41591-020-01179-4
  +Save
• Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
  Merryn Voysey, Sue Ann Costa Clemens, Shabir Ahmed Madhi +97 more
  Lancet (London, England) 2021 DOI: 10.1016/s0140-6736(21)00432-3
  +Save
• Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
  Merryn Voysey, Sue Ann Costa Clemens, Shabir Ahmed Madhi +97 more
  Lancet (London, England) 2020 DOI: 10.1016/s0140-6736(20)32661-1
  +Save